EFFECTS OF P-GLYCOPROTEIN INHIBITION IN THE CENTRAL BIOAVAILABILITY OF CARBAMAZEPINE AND PHENOBARBITAL IN AN EXPERIMENTAL MODEL OF EPILEPSY. Auzmendi J, González N, Mayer M, Opezzo J, Taira C, Lazarowski A, Girardi E. XXXIX Reunión Anual de la

HÖCHT C; AUZMENDI J; GONZÁLEZ N; MAYER M; OPEZZO J; TAIRA C; LAZAROWSKI A; GIRARDI E

CABA, Argentina

Congreso; XXXIX Reunión Anual de la Sociedad Argentina de Farmacología Experimental; 2007

Sociedad Argentina de Farmacología Experimental

The present work examines the participation of the P-glycoprotein (P-gp) in central carbamazepine (CB) and phenobarbital (PB) pharmacokinetics in an experimental model of epilepsy induced by 3-mercaptopropionic acid (MP). Seizures were induced in Wistar rats by injection of MP (45mg/kg) during 10 days. Control rats (C) were injected with saline solution (SS). A concentric microdialysis probe was inserted into hippocampus, in order to monitor CB or PB levels. CB (10 mg.kg-1, i.v.) or PH (20 mg.kg-1, i.v.) was injected 30 min after administration of vehicle (V) or nimodipine (NIMO, 2 mg.kg-1, ip). No differences were found in CB hippocampal levels comparing all groups. Conversely, in rats pretreated with V, hippocampal PB levels were lower in MP rats (maximal concentration (Cmax): 6.2±0.5 µg/ml, p